Israel's Exalenz Diagnostic To Be Used In Pfizer U.S. Hep C Trials
This article was originally published in PharmAsia News
Exalenz Bioscience of Israel has entered into an agreement with U.S.-based Pfizer to use a diagnostic in a mid-stage trial to treat hepatitis C
You may also be interested in...
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.